IMAC Holdings Announces Leadership Succession

Rhea-AI Summary

IMAC Holdings announced a major leadership transition, appointing Faith Zaslavsky as CEO, succeeding Jeff Ervin. This move aims to drive forward its newly acquired assets in the proteomics and precision medicine industry.

Zaslavsky brings 23 years of experience in the genomic space, having previously served as COO and CEO of Theralink Technologies and President of Oncology at Myriad Genetics. Her leadership is expected to enhance IMAC's mission of providing personalized treatment plans for cancer patients.

IMAC's RPPA technology, proven through clinical trials as a superior indicator for drug selection in breast cancer, is set to become an essential test for various cancers. The board now consists of three independent members following the resignation of co-founders Dr. Matt Wallis and Jeff Ervin, with Ervin continuing as a transition consultant.

Positive

• Appointment of Faith Zaslavsky, an experienced leader in genomics and oncology, as CEO.
• Zaslavsky's background includes roles as COO and CEO of Theralink Technologies and President of Oncology at Myriad Genetics.
• IMAC's RPPA technology proven superior in clinical trials for drug selection in breast cancer.
• RPPA technology set to become essential for breast cancer and other conditions.
• Board of directors now comprises three independent members.

Negative

• Resignation of co-founders Dr. Matt Wallis and Jeff Ervin from the board.
• Transition may cause short-term uncertainty among investors.
• Potential risks associated with the commercialization of new technology.

Faith Zaslavsky appointed as CEO to succeed Jeff Ervin

FRANKLIN, Tenn., May 24, 2024 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: BACK) (“IMAC”) today announced leadership transitions to the board of directors and executive team. Faith Zaslavsky has been appointed chief executive officer, succeeding Jeff Ervin, to lead newly acquired assets in the proteomics and precision medicine industry.

“I am excited and honored to join IMAC and continue the mission that Jeff and team created, which is focused on providing better outcomes for patients,” said Ms. Zaslavsky. “In the 23 years of working in the genomic space, I have never been more excited about a product and the brilliant and dynamic individuals who have worked hard to bring this cutting-edge technology to patients and providers. Our technology and the people behind it create a game changing advancement in precision medicine by providing physicians the ability to create a highly specific and personalized treatment plan for patients facing the cancer journey.”

Ms. Zaslavsky previously served as COO and CEO at Theralink Technologies. Prior to Theralink, Ms. Zaslavsky served as President of Oncology for Myriad Genetics. Her responsibilities have included overseeing all commercials functions which include leading Medical Services, Medical Affairs, National and Enterprise Accounts, and Sales and Marketing. She has spent 23 years leading and transforming teams, designing solutions for physicians to support care, and advocating for patients facing a journey with cancer. She also serves on the American Society of Breast Surgeons Foundation Board of Directors.

The RPPA technology acquired has proven through multiple clinical trials to be a superior indicator of the presence of key biomarkers associated with drug selection in Breast Cancer and other cancers. BACK is poised to continue the progress of this technology and establish RPPA as an essential test for all breast cancer patients and many other cancers and other conditions in the near future.

“IMAC has delivered innovative treatments for predictable and safe outcomes to patients since its inception, and I am excited that will continue in the oncology specialty for physicians seeking optimal care for patients with advanced breast cancer,” said Mr. Ervin. “Faith has a tremendous passion for patients and the experience to lead this exceptional technology into commercialization.”

The board of directors will consist of three independent board members effective today. The board accepted the resignation of BACK co-founders Dr. Matt Wallis and Mr. Ervin from the board. Mr. Ervin will serve as a transition consultant.

About IMAC Holdings, Inc. 

IMAC Holdings, Inc. is a clinical research and commercialization company. The Company is focused on innovative medical advancements and care in the oncology and neurological medical specialties. The Company's technology, through its patented phosphoprotein and protein biomarker platform and lab developed tests (LDTs), targets multiple areas of oncology and drug development. Its LDTs are utilized by oncologists in the United States to assist in delivering a targeted treatment plan for their patients with advanced breast cancer. For more information visit www.imacholdings.com.

###

IMAC Investor Contact:
sgardzina@imacholdings.com

FAQ

Who is the new CEO of IMAC Holdings?

Faith Zaslavsky has been appointed as the new CEO of IMAC Holdings, effective May 24, 2024.

What experience does Faith Zaslavsky bring to IMAC?

Faith Zaslavsky has 23 years of experience in the genomic space, previously serving as COO and CEO of Theralink Technologies and President of Oncology at Myriad Genetics.

What is the significance of the RPPA technology for IMAC?

RPPA technology, acquired by IMAC, has been proven through clinical trials as a superior indicator for drug selection in breast cancer and is expected to become essential for various cancers.

What changes have occurred in the board of directors at IMAC?

The board now consists of three independent members following the resignation of co-founders Dr. Matt Wallis and Jeff Ervin.

What role will Jeff Ervin play after stepping down as CEO?

Jeff Ervin will continue as a transition consultant for IMAC Holdings.